Reporting from: European Society of Cardiology Congress September 3-7, 2005, Stockholm Scientific Editors: Michael Petch, Papworth Hospital, Cambridge Man Fai Shiu, Walsgrave Hospital, Coventry James
Reporting from:European Society of Cardiology Congress September 3-7, 2005, StockholmScientific Editors:Michael Petch, Papworth Hospital, CambridgeMan Fai Shiu, Walsgrave Hospital, CoventryJames Tcheng, Duke University, DurhamHarvey White, Green Lane Hospital, AucklandProducer:Derek Thorne
In this edition:
The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress.Keith Foxtalked about new evidence that strengthens the case for aggressive management of patients.
The conference also heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578.Jean Fajadetfrom Toulouse discussed the ENDEAVOR-2 study.
A future option for treating in-stent restenosis by coating a balloon with an anti-proliferative drug and inflating it inside the newly-occluded stent was discussed at the ESC Congress byBruno Schellerwho presented the first study of such a device in humans.
In the treatment of acute myocardial infarction, the 24-country ASSENT-4 study seems to show an overall increase of risk if you use thrombolysis before primary PCI.Frans Van de Werfgave the 30 day analysis.Kim Foxcomments.
Interviews in this edition:
1. Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
Shamir Mehta, McMaster University, Hamilton Ontario
Shamir Mehtaof McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questionedFreek Verheugtof Nijmegen.
COMMENT:Freek Verheugt, Academisch Ziekenhuis, Nijmegen, The Netherlands
Shamir Mehta:
Freek Verheugt:
2. RITA-3 Study Five Year Results: Aggressive Management of Acute Coronary Syndrome Now looks Even Better
Keith Fox, Edinburgh Royal Infirmary
The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress. Keith Fox from Edinburgh told Audio Medica about new evidence that strengthens the case for aggressive management.
3. ASCOT Trial: Better Lower Blood Pressure with Calcium Antagonist and ACE Inhibitor
Peter Sever, Imperial College, National Heart & Lung Institute, London
4. Endeavor: Alternative Drug-Eluting Stent?
Jean Fajadet, Unite de Cardiologie Interventionnelle, Toulouse
The ESC heard the latest on the Endeavor stent, which elutes the sirolimus analogue ABT-578.Jean Fajadetfrom Toulouse told Audio Medica about the findings from ENDEAVOR II study of around 1200 patients.
5. Drug-eluting Stents: Cost-B